Thursday, March 31, 2011

Cogane Clinical Trials Phase II for Parkinson's Disease

The long awaited Cogane trial is recruiting

Is there a rainbow over the PD road?
 If you are between 35 to 75 years of age and have a confirmed early-stage idiopathic Parkinson's disease within the last two years and are not receiving any PD treatment, you may be eligible for NCT01060878. Women of child-bearing potential are excluded although the study is open to both genders. The other exclusionary conditions are prior neurosurgical PD procedures and history or severe psychiatric illness.

The investigation into the efficacy, safety and tolerability of Cogane has now reached the phase II stage of clinical testing.  This trial will be a double-blind, placebo-controlled study.  We are not sure if it will be followed by an open label trial - wouldn't that be terrific if this GDNF approach is actually effective. 

NCT01060878  is sponsored by Phytopharm. The investigation of Cogane (PYM50028) in Early-stage PD is now recruiting at the following locations:

In the United States
La Jolla, Sacremento and Sunnyvale, California        
Manchester and New Haven, Connecticut
Chicago and Sprinfield, Illinois
St Louis, Missouri
Manhasset, NY

In Canada:
London, Ontario    
Ottawa, Ontario
Quebec City, Quebec

In the United Kingdom
Luton, Bedfordshire
Newcastle upon Tyne, Tyne and Wear

additional reading:
Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease
There is additional ongoing research: The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: Protein distribution and the glial response

No comments:

Post a Comment

Welcome to Parkinsons Focus Today.
We are delighted to hear from you by comment here
or through email as found in Contact Us.

Please do not include email addresses if leaving a comment online.
Email addresses are used only for email responses.

Spammers take note: your messages will not be published. The comments section is for an exchange of ideas, not for backlinks.